Vontobel Holding’s Arcturus Therapeutics ARCT Stock Holding History

Vontobel Holding’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-29,735	Closed	-$690K	–	1100
2024 Q3	$690K	Sell	29,735 -989	-3%	-$21.2K	﹤0.01%	691
2024 Q2	$748K	Buy	+30,724	New	+$932K	﹤0.01%	656
2023 Q4	–	Sell	-40,659	Closed	-$1.04M	–	1109
2023 Q3	$1.04M	Sell	40,659 -1,042	-2%	-$32.1K	0.01%	571
2023 Q2	$1.2M	Sell	41,701 -15,468	-27%	-$421K	0.01%	556
2023 Q1	$1.37M	Sell	57,169 -8,689	-13%	-$156K	0.01%	508
2022 Q4	$1.12M	Sell	65,858 -6,994	-10%	-$122K	0.01%	548
2022 Q3	$1.08M	Sell	72,852 -3,958	-5%	-$66.4K	0.01%	526
2022 Q2	$1.21M	Buy	76,810 +38,307	+99%	+$752K	0.01%	498
2022 Q1	$1.04M	Sell	38,503 -1,515	-4%	-$38.7K	0.01%	611
2021 Q4	$1.48M	Sell	40,018 -149	-0.4%	-$6.07K	0.01%	530
2021 Q3	$1.92M	Buy	40,167 +1,015	+3%	+$45.5K	0.02%	449
2021 Q2	$1.32M	Buy	+39,152	New	+$1.33M	0.01%	528

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vontobel Holding's ARCT Position: Q4 2024 in Review

Vontobel Holding sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 29,735 shares — an estimated $690K sold.

Vontobel Holding first reported a position in ARCT in Q2 2021 and held it in 12 quarters. The position peaked at $1.92M in Q3 2021. 148 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

Vontobel Holding reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
Vontobel Holding sold 29,735 Arcturus Therapeutics shares in Q4 2024, an estimated $690K.
Vontobel Holding first reported a position in Arcturus Therapeutics in Q2 2021 and held it in 12 quarters.
Vontobel Holding's Arcturus Therapeutics position peaked at $1.92M in Q3 2021.
148 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Vontobel Holding's 13F filing for Q4 2024, filed 30 Jan 2025.